Hereditary Cerebral Small Vessel Disease
Ever Neuro Pharma GmbH is involved in clinical research focused on Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL), a rare inherited disorder affecting the brain’s small blood vessels and associated with progressive white matter disease, recurrent stroke, and cognitive decline.
- CADASIL
- Genetically confirmed hereditary arteriopathy
- Subcortical infarcts
- Leukoencephalopathy
The sponsor’s research interest centers on neurological conditions linked to cerebrovascular pathology and long-term impairment of brain function.
Neurological Symptom Burden
Its clinical activity reflects interest in the management of neurological deficits associated with CADASIL, including impairment of cognition, motor function, and overall daily functioning in affected patients.
- Cognitive impairment
- Functional disability
- Stroke-related sequelae
- Progressive neurological decline
This area places emphasis on clinical outcomes relevant to chronic neurovascular disease.
Neuroprotective Therapy
The sponsor funds research evaluating Cerebrolysin in the context of CADASIL, indicating a therapeutic interest in neuroprotective and brain-supportive treatments for inherited vascular brain disorders.
- Cerebrolysin
- Neuroprotection
- Brain metabolism
- Neurological recovery
Research in this domain is directed toward treatment options for patients with chronic, progressive central nervous system involvement.
